Mixed Vector Immunization With Recombinant Adenovirus and MVA Can Improve Vaccine Efficacy While Decreasing Antivector Immunity
Arturo Reyes‐Sandoval(Instituto Politécnico Nacional), Adrian V. S. Hill(Jenner Institute), Karolis Bauza(Jenner Institute), Matthew G. Cottingham(University of Oxford), Matthew D. J. Dicks(University of Oxford), David Wyllie(John Radcliffe Hospital), Dong Wang(Sichuan University), Christine S. Rollier(University of Oxford), Choon-Kit Tang(University of Oxford), Rhea J. Longley(Walter and Eliza Hall Institute of Medical Research)
Cited by 40
Related Papers
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial
|The Lancet|2020|2.6k
T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial
|Nature Medicine|2020|643
Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial
|The Lancet|2001|528
Efficacy of a low-dose candidate malaria vaccine, R21 in adjuvant Matrix-M, with seasonal administration to children in Burkina Faso: a randomised controlled trial
|The Lancet|2021|457
Association between an MHC Class II Allele and Clearance of Hepatitis B Virus in the Gambia
|New England Journal of Medicine|1995|439